Navigation Links
Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
Date:7/27/2009

Emerging Therapies to Treat Metastatic Hormone-Refractory Prostate Cancer Will Capture More Than One-Third of the Market, According to a New Report from Decision Resources

WALTHAM, Mass., July 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic hormone-refractory population, most notably Dendreon's Provenge.

The new Pharmacor report entitled Prostate Cancer finds that therapies in the metastatic hormone-refractory population -- for which there is significant unmet need -- will capture more than one-third of the overall prostate cancer drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the report, the high sales of the emerging therapies are due to the expectation that these agents can improve overall survival in the hormone-refractory metastatic setting, an achievement attained only by Sanofi-Aventis's Taxotere and, more recently, by the therapeutic cancer vaccine Provenge. Several agents appeared promising in early-stage development but failed in Phase III clinical trials, highlighting the challenge of this achievement.

Through 2018, the launches of Provenge, Roche/Chugai's Avastin, AstraZeneca's zibotentan, Johnson & Johnson's abiraterone and Algeta's Alpharadin will fuel market growth. Specifically, sales of Avastin will be driven by its use in combination with Taxotere and sales of Alpharadin will be driven by its use in patients who are not suitable for treatment with Taxotere, according to the report.

"We forecast Taxotere's patient share will increase in the metastatic hormone-refractory setting as a result of its use in combination with emerging agents such as Avastin," said Decision Resources Analyst Andrew Merron, Ph.D. "The use of Taxotere to treat patients not previously receiving cytotoxic agents will increase over the next decade as oncologists are expected to take a more prominent role in the treatment of prostate cancer patients."

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Reigniting Hope for Therapeutic Cancer Vaccines: What Impact Will Provenge Have on the Prostate Cancer Drug Market? This webinar will be held on Wednesday, August 19, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at 781-296-2597 or by email at ccomfort@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                    Decision Resources, Inc.
    Christopher Comfort                   Elizabeth Marshall
    781-296-2597                          781-296-2563
    ccomfort@dresources.com               emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
2. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
3. Blue Cross And Blue Shield Association Survey Shows Consumer Driven Health Plan Enrollees Are Taking More Control of Their Healthcare
4. UniCare Introduces Consumer-Driven Health Products to Give Consumers a Bigger Role in Health Care Decisions
5. Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products
6. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
7. World Health Report Rankings Driven by Ideology, Skewed Data
8. New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows
9. Successful Community-Driven Efforts Against HIV/AIDS Highlighted in Conference Panel
10. Tongue-Driven Device Aids Handicapped
11. Members of consumer-driven health plans choosing less care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: